KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biocryst Pharmaceuticals (BCRX) Depreciation & Amortization (CF) (2023 - 2025)

Biocryst Pharmaceuticals (BCRX) has disclosed Depreciation & Amortization (CF) for 9 consecutive years, with $331000.0 as the latest value for Q1 2025.

  • For the quarter ending Q1 2025, Depreciation & Amortization (CF) rose 8.17% year-over-year to $331000.0, compared with a TTM value of $331000.0 through Dec 2025, down 73.43%, and an annual FY2025 reading of $1.4 million, up 11.48% over the prior year.
  • Depreciation & Amortization (CF) was $331000.0 for Q1 2025 at Biocryst Pharmaceuticals, up from $309000.0 in the prior quarter.
  • Across five years, Depreciation & Amortization (CF) topped out at $423000.0 in Q4 2023 and bottomed at $306000.0 in Q1 2024.
  • Average Depreciation & Amortization (CF) over 3 years is $359111.1, with a median of $331000.0 recorded in 2025.
  • The sharpest move saw Depreciation & Amortization (CF) fell 26.95% in 2024, then increased 8.17% in 2025.
  • Year by year, Depreciation & Amortization (CF) stood at $423000.0 in 2023, then dropped by 26.95% to $309000.0 in 2024, then increased by 7.12% to $331000.0 in 2025.
  • Business Quant data shows Depreciation & Amortization (CF) for BCRX at $331000.0 in Q1 2025, $309000.0 in Q4 2024, and $311000.0 in Q3 2024.